NASDAQHealth CareMedical DevicesSnapshot 2026-07-23
Reading IART? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a turnaround story in the healthcare sector. The current thesis state is intact, supported by strong recent financial performance despite ongoing losses.
The market appears to have priced in a justified valuation, reflecting a low expectations gap compared to peers. IART is seen as cheap relative to its industry competitors.
Management has provided mixed guidance for revenue and earnings per share in 2026, with recent performance showing limited progress. The near-term risk of missing earnings is low, but the company must navigate a competitive landscape.
The thesis hinges on the performance of sector bellwethers like ABT, SYK, and MDT. Positive earnings and guidance from these companies could bolster IART, while any negative shifts could pose risks.
Over the next 1 to 3 years, IART's performance will depend on its ability to meet guidance and the overall health of the healthcare sector. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improvement, indicating that the company's recent financial performance is holding strong. There are no current threats identified that could weaken this positive outlook.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: This will help assess if the company can sustain growth momentum or if it is losing market share.
Confirms:Q1 2026 organic revenue growth is reported below 1.3%.
Disproves:Q1 2026 organic revenue growth is reported above 1.3%.
Why it matters: Stable or growing revenue means success in changes made.
Confirms:Q1 2026 revenue growth stabilizes or improves above 1.3% year over year.
Disproves:Q1 2026 revenue growth declines below 1.3% year over year.
Why it matters: An EPS update will indicate how well the company is managing costs and profits.
Confirms:EPS guidance raised above $1.00 for 2026.
Disproves:EPS guidance lowered below $0.80 for 2026.
Why it matters: A clear plan from the new CEO could help calm investors after the change.
Confirms:A press release detailing a new strategic plan or vision for the company.
Disproves:No announcement or vague statements about future direction from the new CEO.
Why it matters: A higher adjusted EBITDA margin means the company is more efficient. This leads to more profit.
Confirms:Adjusted EBITDA margin goes above 19.4% in Q2 2026.
Disproves:Adjusted EBITDA margin falls below 19.4% in Q2 2026.
Why it matters: The new CEO's plan will change the company's path and affect investor trust.
Confirms one read:New plans were announced that match growth goals.
Confirms the other:There are no new plans or a delay in the strategy rollout.
Why it matters: This update shows if the company is making more money. It shows management's faith in future earnings.
Confirms:EPS guidance for 2026 is updated to between $2.40 and $2.50.
Disproves:EPS guidance for 2026 is lowered below $2.40.
Why it matters: Revenue growth shows how well the company is bouncing back.
Confirms one read:Revenue growth stays above 3% each year in the next reports.
Confirms the other:Revenue growth drops below 0% year over year.
Why it matters: The new CEO's clear goals can guide the company and boost investor trust.
Confirms one read:The new CEO presents a clear and actionable strategic plan during the earnings call.
Confirms the other:The new CEO fails to provide a clear strategic plan during the earnings call.
Why it matters: Stuart Essig's return as CEO aims to strengthen execution and performance. This will show if the leadership change is effective.
Confirms:Customers liked the product. Key numbers got better in the next earnings call.
Disproves:There may be ongoing operational issues or bad customer feedback in the next earnings call.
Why it matters: This guidance will show if the company can sustain its growth trajectory.
Confirms one read:Management expects revenue growth to be over 10% for 2026.
Confirms the other:Management expects revenue growth to be under 5% for 2026.
Why it matters: This update will show if the company can meet its growth goals for 2026.
Confirms:Q2 revenue guidance raised above 5% growth year over year.
Disproves:Q2 revenue guidance lowered below 0% growth year over year.
Why it matters: When revenue guidance is confirmed, it shows management can grow the company. This is important for investor trust.
Confirms:Q2 2026 revenue reported between $410 million and $425 million, showing growth.
Disproves:Q2 2026 revenue was below $410 million. This shows there are challenges in execution.
Why it matters: Adjusted EPS performance shows if the company is on track to meet its financial goals. This impacts investor perception.
Confirms:Adjusted EPS was between $0.44 and $0.52. This shows strong performance in operations.
Disproves:Adjusted EPS was below $0.44. This suggests there are ongoing financial problems.
